Abiopharma

🔍 Dillione Janet (Director)

Company: CorMedix Inc. (CRMD)

Report Date: 2025-12-09

Detailed Transactions and Holdings:

• Acquired 19,000 shares of Common Stock at $9.55 per share (Direct)
  Date: 2025-12-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 67,473.00 | transaction_form_type: 4
• Acquired 15,000 shares of Common Stock at $5.63 per share (Direct)
  Date: 2025-12-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 82,473.00 | transaction_form_type: 4
• Sold 34,000 shares of Common Stock at $12.0 per share (Direct)
  Date: 2025-12-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 48,473.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 19,000 shares of Stock Option (Right to Buy Common Stock) at $9.55 per share (Derivative)
  Date: 2025-12-09 | Code: M | Expires: 2026-02-21 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2
• Sold 15,000 shares of Stock Option (Right to Buy Common Stock) at $5.63 per share (Derivative)
  Date: 2025-12-09 | Code: M | Expires: 2030-02-25 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: This transaction was executed in multiple trades at prices ranging from $12.00 to $12.02, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected
• F2: These options were granted on 02/21/2016. These options are fully vested.
• F3: These options were granted on 02/25/2020. These options are fully vested.